

Wegovy[®] (semaglutide) – Updated dosing

- On July 21, 2023, the [FDA approved](#) an update to the drug label for [Wegovy \(semaglutide\)](#) to include 1.7 mg subcutaneous weekly as an additional maintenance dose for use as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.
 - Previously, Wegovy was only approved with a maintenance dose of 2.4 mg once weekly.
- In adults, Wegovy is initiated at a dosage of 0.25 mg injected subcutaneously (SC) once-weekly. The updated dose escalation schedule is presented in the table below.

Treatment	Weeks	Once weekly SC dosage
Initiation	1 through 4	0.25 mg
Escalation	5 through 8	0.5 mg
	9 through 12	1 mg
	13 through 16	1.7 mg
Maintenance	17 and onward	1.7 mg or 2.4 mg

- Wegovy is also approved in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity).
 - The maintenance dosage of Wegovy in pediatric patients aged 12 years and older is 2.4 mg weekly.
- Wegovy carries a boxed warning for risk of thyroid C-cell tumors.